Abstract:Diabetes mellitus (DM) is the most commonly occurring cause of neuropathy around the world and is beginning to grow in countries where there is a risk of obesity. DM Type II, (T2DM) is a common age-related disease and is a major health concern, particularly in developed countries in Europe where the population is aging. T2DM is a chronic disease which is characterised by hyperglycemia, hyperinsulinemia and insulin resistance, together with the body's inability to use glucose as energy. Such metabolic disorder produces a chronic inflammatory state, as well as changes in lipid metabolism leading to hypertriglyceridemia, thereby producing chronic deterioration of the organs and premature morbidity and mortality. The pathology's effects increase cerebral damage, leading to the rapid onset of neurodegenerative diseases. Hyperglycemia causes oxidative stress in tissues which are susceptible to the complications involved in diabetes, including peripheral nerves. Other additional mechanisms include activation of polyol aldose reductase signalling accompanied by protein kinase C (PKC)-ß activation, poly(ADP ribose) polymerase activation, cyclooxygenase (COX) 2 activation, endothelial dysfunction, altered Na+/K+ ATPase pump function, dyslipidaemia and perturbation of calcium balance. All the forgoing has an impact on neuron activity, mitochondrial function, membrane permeability and endothelial function. These biochemical processes directly affect the neurons and endothelial tissue, thereby accelerating cerebral aging by means of peroxidation of the polyunsaturated fatty acids and thus injuring cell membrane integrity and inducing apoptosis in the glial cells. The Central Nervous System (CNS) includes two types de glial cells: microglia and macroglia (astrocytes, oligodendrocytes and radial cells which include Bergmann cells and Müller cells). Glial cells constitute more than 90% of the CNS cell population. Human studies have shown that some oral antidiabetic drugs can improve cognition in patients suffering mild cognitive impairment (MCI) and dementia [1, 2]. While it is still unclear whether diabetes management will reduce MCI and Alzheimer's disease (AD), incidence, emerging evidence suggests that diabetes therapies may improve cognitive function. This review focuses three aspects: the clinical manifestation of diabetes regarding glial and neuronal cells, the association between neurodegeneration and diabetes and summarises some of the pharmacogenomic data obtained from studies of T2DM treatment, focusing on polymorphisms in genes affecting pharmacokinetics, pharmacodynamics and treatment outcome of the most commonly-prescribed oral anti-diabetic drugs (OADs).

Advancing the understanding of diabetic encephalopathy through unravelling pathogenesis and exploring future treatment perspectives

Progress in the Pathogenesis of Diabetic Encephalopathy: The Key Role of Neuroinflammation

Morphological and Pathological Characteristics of Brain in Diabetic Encephalopathy

Autophagy and Diabetic Encephalopathy: Mechanistic Insights and Potential Therapeutic Implications

Mechanistic Insights and Potential Therapeutic Implications of NRF2 in Diabetic Encephalopathy

Electroacupuncture Improves Learning and Memory Deficits in Diabetic Encephalopathy Rats by Regulating the Nrf2/HO-1 Pathway

Pathogenic Mechanisms and Drug Research Situation in Diabetic Encephalopathy

Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders

Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions

Huang-Lian-Jie-Du Decoction Alleviates Diabetic Encephalopathy by Regulating Inflammation and Pyroptosis via Suppression of AGEs/RAGE/NF-κB Pathways

Prospects of Antidiabetic Drugs in the Treatment of Neurodegenerative Disease

Resveratrol ameliorates diabetic encephalopathy through PDE4D/PKA/Drp1 signaling

Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review

Advanced Glycosylation End Products Induced Synaptic Deficits and Cognitive Decline Through ROS-JNK-p53/miR-34c/SYT1 Axis in Diabetic Encephalopathy

Diabetes-Related Neurological Implications and Pharmacogenomics

Inside the Diabetic Brain: Role of Different Players Involved in Cognitive Decline

[Contributions of impaired adult hippocampal neurogenesis to occurrence and development of diabetic encephalopathy]

Receptor for Advanced Glycation End Product, Organ Crosstalk, and Pathomechanism Targets for Comprehensive Molecular Therapeutics in Diabetic Ischemic Stroke

Encephalopathies: the emerging diabetic complications

Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy

Molecular and biochemical mechanisms of diabetic encephalopathy